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Background: Hematopoietic Stem Cell Transplantation (HSCT) is known to induce the inhibitory immune receptor
NKG2A on NK cells of donor origin. This occurs in allogeneic recipients, in both the haploidentical and HLA-matched
settings.
Methods: To gain further insight, not only NKG2A, but also the activating receptors NKG2C and NKG2D were assessed by
flow cytometry. Immunophenotyping was carried out not only on CD56+ but also on CD8+ lymphocytes from leukemia
and lymphoma patients, receiving both HLA-matched (n = 7) and autologous (n = 5) HSCT grafts. Moreover, cognate
NKG2 ligands (HLA-E, MICA, ULBP-1, ULBP-2 and ULBP-3) were assessed by immunohistochemistry in diagnostic
biopsies from three autotransplanted patients, and at relapse in one case.
Results: All the NKG2 receptors were simultaneously up-regulated in all the allotransplanted patients on CD8+ and/or
CD56+ cells between 30 and 90 days post-transplant, coinciding with, or following, allogeneic engraftment. Up-regulation
was of lesser entity and restricted to CD8+ cells in the autotransplantation setting. The phenotypic expression
ratio between activating and inhibitory NKG2 receptors was remarkably similar in all the patients, except two
outliers (a long survivor and a short survivor) who surprisingly displayed a similar NKG2 activation immunophenotype.
Tumor expression of 2 to 3 out of the 5 tested NKG2 ligands was observed in 3/3 diagnostic biopsies, and 3 ligands
were up-regulated post-transplant in a patient.
Conclusions: Altogether, these results are consistent with a dual (activation-inhibition) NK cell re-education mode, an
innate-like T cell re-tuning, and a ligand:receptor interplay between the tumor and the immune system following HSCT
including, most interestingly, the up-regulation of several activating NKG2 ligands. Turning the immune receptor balance
toward activation on both T and NK cells of donor origin may complement ex vivo NK cell expansion/activation strategies
in unmanipulated patients.
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Natural Killer (NK) cells bearing variable Killer
Immunoglobulin-like Receptors (KIR) bind highly poly-
morphic class I Human Leukocyte Antigens (HLA-A,
−B,−C), mount Graft versus Tumor (GvT) responses,
and influence the outcome of patients with hematologic
malignancies undergoing Hematopoietic Stem Cell Trans-
plantation (HSCT). Unlike donor T cells, NK cells mediate
limited Graft versus Host (GvH) reactions. Therefore,
clinical transplantation protocols are being increasingly
tailored on NK cells, in order to exploit a ligand:receptor
mismatch of some kind (genetic and/or phenotypic)
between any residual tumor cells in the recipient and the
NK cell-repleted graft [1–3].
A full HLA haplotype mismatch occurs in haploidenti-
cal HSCT, with certain HLA-KIR combinations engen-
dering optimal clinical effects. Similar mismatches may
also arise in a fully HLA-matched allograft setting, since
KIR segregate and are inherited independently from
HLA. Even during hematopoietic self-replacement
(autologous transplantation), approximately 60 % of the
patients are expected to display the so-called ‘missing
KIR’ phenotype, in that they express inhibitory KIRs that
do not find a cognate HLA ligand on tumor cells. Although
unlicensed and hyporesponsive, these NK cells may become
cytokine-activated under appropriate conditions, positively
affecting the outcome of hematopoietic malignancies and
neuroblastoma [4, 5].
The genetic/phenotypic mismatch paradigm based
on the variable KIRs is pervasive. However, both T and
NK cells also express conserved (displaying little or no
known polymorphism) receptors that sense changes in
ligand expression associated with transformation and
tumor cell stress. These may also find application in clinical
transplantation. For instance, NKG2 receptors belong
to a lectin-like protein family with inhibitory (NKG2A)
as well as activating (NKG2C and NKG2D) members
[6]. NKG2A and NKG2C bind the non-classical HLA
class I molecule HLA-E. NKG2D binds the Major
Histocompatibility Class I-like molecules A and B
(MICA/B), and UL16 Binding Proteins (ULBPs). NKG2D
ligands signal cellular stress in the un-manipulated host
and, like HLA-E, they are overexpressed in tumor cells
[7–11]. Conceivably, ligand overexpression and NKG2
receptor up-regulation may induce GvT through enhanced
immune challenge, rather than overt donor-recipient
mismatch.
To our knowledge, at least 7 studies [12–18] have
examined NKG2 receptor expression in HSCT (summa-
rized in Additional file 1: Table S1). There is general
agreement that the inhibitory NKG2A receptor is up-
regulated on immature, engrafting NK cells at an early
education stage, whereas the triggering NKG2C and
NKG2D receptors have been the subject of a fewconflicting studies. NKG2D up-regulation was observed
in 2/3 studies [14, 16, 17]. NKG2C up-regulation was
seen in NK cells from cord blood [18] but not adult
HSCT grafts [16]. Changes in NKG2 expression have
never been correlated with engraftment kinetics, and the
information available on autologous HSCT is limited to
one study [12]. More in general, NKG2 receptors have
never been assessed on CD8+ T cells (Additional file 1:
Table S1). This is unfortunate, since cytotoxic T lympho-
cytes, like NK cells, integrate NKG2 receptor signaling
in their lytic responses [19, 20]. Finallly, HLA-E,
MICA/B, and ULBPs were never assessed on the tu-
mors of transplanted patients. Thus, the phenotypic
changes of NKG2 ligand:receptor pairs following HSCT
are to our knowledge poorly defined, and their possible
implications in GvT remain so far unappreciated.
To provide an overview of NKG2A, NKG2C and
NKG2D up-regulation in different HSCT settings, on
different immune effectors, in different hematologic ma-
lignancies, at different times post-transplant, and relative
to engraftment, we have immunophenotyped both CD8
and CD56 lymphocytes from the peripheral blood of two
series of representative recipients of HLA-matched allo-
geneic (n = 7) and autologous (n = 5) grafts. We have
also assessed HLA-E, MICA, ULBP-1, ULBP-2 and
ULBP-3 expression in 3 lymphoma specimens from
autotransplanted patients. Results to be shown provide
evidence for common, remarkably homogeneous post-
HSCT phenotypic patterns, for the expression of NKG2
ligands on the tumor and cognate immune receptors on
the lymphoid graft, and for phenotypic/clinical outliers




The study was specifically approved by the competent
Ethical Board (IRB 599/14). All patients and donors
agreed to the research use of their diagnostic and bio-
logical specimens by signing an informed consent. Tables 1
and 2, as well as supporting information, summarize the
features of the patients and treatments.
Flow cytometry
Whole blood was collected in BD Biosciences vacutainer
collection tubes K2E (EDTA) at room temperature.
Plasma was removed by washing, and 100 μl aliquots of
packed blood cells were pre-incubated with 1 μg of
murine Ig to saturate Fc receptors, and then stained
(two-color fluorescence) by simultaneous incubation
for 30 min on ice with an FITC-conjugated mAb to
either CD8 (clone DK25 from Dako) or CD56 (clone
MEM-188 from Euroclone), and with PE-conjugated
mAbs to NKG2A, NKG2C or NKG2D (clones 131411,
Table 1 Allotransplanted patients















149 32 AML U PB MAC No - 69 156 Dead Relapse/Progression
150 26 DLBCL R PB RIC I 38 no 149 Dead Infection
151 49 AML R PB MAC IV 12 124 293 Dead Fungal Infection -
Rejection/Poor graft
Functionf
152 33 B-ALLg U PB MAC III 88 no 137 Dead Infection
153 37 SAA R PB + BM MAC II 40 no 307 Dead Unknown
154 46 AMLh R PB MAC No - 299 365 Dead Haemorrhage - CNS
Toxicity
155 42 MM R PB MAC No - 151 485 Dead Relapse/Progression
aAML, acute myeloid leukemia; DLBCL, Diffuse Large B cell Lymphoma; B-ALL, B-cell Acute Lymphoid Leukemia; SAA, Severe Aplastic Anemia;
MM, Multiple Myeloma
bMatched related (R) and matched unrelated (U) donor
cPB, peripheral blood; BM, bone marrow
dMAC, MyeloAblative Conditioning regimen; RIC, Reduced Intensity Conditioning
eaGvHD, acute Graft versus Host Disease
fremission induced by chemotherapy upon relapse (day 124)
gPatient previously diagnosed (year 1991) with CML t(9;22)
hSubclass III, according to the French American British classification of AML
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tems). A mouse Ig isotype cocktail, and the CD4/CD8
simultest (both from BD Biosciences) were used for
fluorescence calibration. At the end of the incubation, red
blood cells were lysed by FACS lysing solution (BD Biosci-
ences 92–0002) for 15 min at room temperature in the
dark. Gated mononuclear cells were read and analyzed in
a FACScan by CellQuest (BD Biosciences).
Variable Nucleotide Tandem Repeat (VNTR) assay
Genomic DNAs were extracted from the Peripheral
Blood Mononuclear Cells of both recipients and donors.
Chimerism was assessed by Quantitative Real-Time PCR
(QRT-PCR) amplification as described [21], and expressed
as the percentage of donor DNA in sample DNA. For fur-
ther details see Additional file 1: Materials and Methods.Table 2 Autotransplanted patients
Patient Age Diagnosisa Status at
transplantb
Source of graftc Conditioning reg
187 60 AML 1st CR PB IBU
188 19 DLBCL 1st PR PB BEAM
189 25 NHL 1st CR PB BEAM
190 50 HL 2nd CR PB BEAM
191 51 MM 1st PR PB MEL200
aAML, Acute Myeloid Leukemia; DLBCL, Diffuse Large B Cell Lymphoma; NHL, Non-H
bCR, complete remission; PR, partial remission
cPB: CD34− peripheral blood autologous stem cells
dBEAM: Carmustine, Etoposide, Cytarabine, Melphalan; IBU: Idarubicine, Busulphan;Immunohistochemistry
Immunohistochemistry was performed on all the avail-
able diagnostic biopsies from patients receiving auto-
transplants. Antigen retrieval (dewaxing, rehydration
and heating) of Formalin Fixed Paraffin Embedded
(FFPE) tissues, and staining with the HLA-E-specific
mAb MEM-E/02 were performed as described [22].
Rabbit polyclonal antibodies used in this study were:
ab93170 to MICA (AbCAM, Cambridge, UK), NBP1-
80856 to ULBP-1, 27080002 to ULBP-2, and NBP2-
31866 to ULBP-3 (Novus Bio, Littleton, CO, USA). As
recommended by the manufacturers, antigen retrieval
was carried out at pH 6.0 in all cases except that for
ULBP-2 (pH 8.0). Since these antibodies are polyclonal,
we validated their specificity on a panel of cell lines









861 1239 Dead Relapse/Progression
odgkin’s Lymphoma; HL, Hodgkin’s Lymphoma; MM, multiple myeloma
MEL200: Melphalan
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these antigens, as indicated in the antibody leaflets.
Sections of FFPE cell pellets and tissues were stained
with a wide range of antibody dilutions, and for each
antibody a working dilution was identified resulting in
optimal staining of positive specimens with no detect-
able background on flow-cytometry-unreactive cell
lines, as follows: antibodies to MICA and ULBP-1
(1:50); antibodies to ULBP-2 and ULBP-3 (1:500).
Staining was revealed by a supersensitive streptavidin-
biotin immunoperoxidase system (Biogenex, Menarini,
Italy). Staining scores were: 0 (from undetectable to
detectable staining in <10 % of tumor cells); 1 (>10 %
but <50 %); 2 (>50 % but <80 %); 3 (>80 %).
Results
Up-regulation of NKG2A, NKG2C and NKG2D in CD8+ T
lymphocytes and CD56+ NK cells from allotransplanted
patients
Blood was obtained before and after transplant (at days
0, 30 and 90; T0, T30 and T90) from the 7 patients listed
in Table 1, and from their respective HLA-matched
donors prior to donation. In analogy with previous studies,
and to permit comparisons with the available data, the
levels of NKG2A (inhibitory), as well as NKG2C and
NKG2D (activating) immune receptors were assessed on
CD8+ and CD56+ cells by two-color flow cytometry. Repre-
sentative results of CD8+ cells from patient 154 (Fig. 1a-d),
and CD56+ cells from patient 153 (Fig. 1e-h) show that per-
centages and mean fluorescence intensities (mfi) values of
NKG2A, NKG2C and NKG2D were simultaneously and
drastically increased at T90. Increased NKG2 expression in
CD8− and CD56− cells from both patients was also visible
(Fig. 1b, d, f and h), demonstrating generalized up-
regulation on both CD8+ and CD56+ cells from both
patients.
This may be more clearly appreciated when the
NKG2 expression data from all the patients and
donors are graphically displayed (Fig. 2). As shown
in this synopsis, the percentage of double-positives
(CD8+/NKG2A+, CD8+/NKG2C+, CD8+/NKG2D+, CD56+/
NKG2A+, CD56+/NKG2C+, and CD56+/NKG2D+) is
plotted in abscissae, and the corresponding NKG2A,
NKG2C, or NKG2D mfi value (calculated by taking
into account the events in the upper and lower right
quadrants) is plotted in ordinates. As a result, percent
positives and mfi are factored into a single parameter, e.g.
the distance (slant) from the plot origin: the greater is the
distance, the greater is the up-regulation (Fig. 2). A slant
value may also be calculated for each receptor and time
point by multiplying the percent of positive cells and
mfi values, as described in Additional file 1. Pearson’s
correlation coefficients among series of NKG2A, NKG2B
and NKG2C slant product values (Additional file 1:Table S2A), demonstrated highly significant correlations.
Thus, the three NKG2 receptors are simultaneously up-
regulated after transplant in most cases. From the synopsis
in Fig. 2 and Additional file 1: Table S2A it may be con-
cluded that: (a) NKG2A, NKG2C and NKG2D were
expressed at very low levels in the pre-transplant CD8+
and CD56+ cells from both donors and recipients; (b)
essentially all NKG2 receptors were up-regulated in both
CD8+ and CD56+ cells from all the patients, with
occasional selective enhancements in individual pa-
tients; (c) optimal up-regulation occurred at day 90
in all patients except pt. 155, displaying a more
marked enhancement at day 30 than at day 90; (d) up-
regulation occurred independently of, and with no obvious
correlation with, either the clinical pathological features or
the success in donor cell engraftment (see Table 1); and
lastly (e) up-regulation also occurred in a patient trans-
planted for Severe Aplastic Anemia (pt. 153, see Table 1),
e.g. a non-neoplastic hematologic condition, although with
considerable potential for neoplastic evolution.
As reported previously [12–15], antibodies to KIR2DL1
and KIR2DL2, included as controls, detected either no
change or a moderate decrease in expression (not shown).
Finally, significant post-transplant increases in CD56
mfi values were also observed (T0 as compared to
T90; p = 0.018 upon two-tailed paired Student t test;
Additional file 1: Table S3), suggesting an overall immature
phenotype of engrafting (see below) NK cells.
Engraftment and NKG2A/C/D up-regulation
Next, we compared the kinetics of NKG2 receptor up-
regulation and engraftment, as assessed by a VNTR assay
(see Materials and Methods). Five of the 6 patients tested in
a full T0-T30-T90 time course had essentially completed en-
graftment by day 30 (Fig. 3). NKG2 up-regulation occurred
either at the time of engraftment (pts. 150, 155 and the
poor-engrafting pt. 154) or later (pts. 151, 152, and 153),
clearly showing that it occurs on cells of donor origin.
There was no obvious correlation between entity or timing
of NKG2 up-regulation and successful engraftment.
Up-regulation of NKG2A, NKG2C and NKG2D in CD8+ T
lymphocytes and CD56+ NK cells from autotransplanted
patients
Similar to allotransplantation, autotransplantation re-
sulted in NKG2A, NKG2C and NKG2D up-regulation
(increases in both the percentage of positive cells and
mfi). However, up-regulation was clearly detected in only
14/30 flow cytometry determinations (Fig. 4, grey
panels), most often in CD8+ T lymphocytes, and it was
invariably of much lesser entity. As a result of weaker
and T cell-selective up-regulation, correlation coeffi-
cients among NKG2A, NKG2C and NKG2D, calculated

































































































Fig. 1 Flow cytometry evaluation of the expression of NKG2A and NKG2D in CD8+ and CD56+ WBCs from allotransplanted patients. WBCs obtained
from patients 154 (a-d) and 153 (e-h) at the indicated times (relative to HSCT) were double-stained with mAbs to either CD8 or CD56 (abscissae), and
to either NKG2A or NKG2D (ordinates)
Picardi et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:98 Page 5 of 11allotransplantation (Additional file 1: Table S2B). Like-
wise, CD56 stain increased to a lesser extent and in a
minority of autotransplanted patients (Additional file 1:
Table S3). These results demonstrate that NKG2 recep-
tor up-regulation, although optimal in an allogeneic set-
ting, also occurs as a result of autotransplantation.NKG2 receptor up-regulation and clinical data
The NKG2 activation/inhibition balance was empirically
estimated, as described in Additional file 1: Results, by
calculating an activation/inhibition ratio, termed R(act/
inh). Higher R(act/inh) values identify patients in which
the NKG2C/D receptors are up-regulated to an extent
CD8 CD56
































donor time 0 recipient time 0 (pre-transplant, T0) recipient day 90 post-transplant (T90)recipient day 30 post-transplant (T30)
NKG2A NKG2C NKG2D NKG2A NKG2C NKG2D
Fig. 2 Quantitative evaluation of NKG2A, NKG2C and NKG2D levels at different times following allogeneic HSCT. Flow cytometry data obtained
from 7 patients were graphically elaborated as described in the text. The results were expressed as a 2D plot (percent positives in abscissae and
mfi in ordinates) separately displaying, for each patient, the time-course of the increases in NKG2A, NKG2C, and NKG2D levels, and the percentages of
NKG2-positive CD8+ and CD56+ cells
Picardi et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:98 Page 6 of 11greater than NKG2A. When R(act/inh) was plotted vs
survival (Additional file 1: Figure S1), values were com-
prised within a narrow range in 10/12 patients, showing
that the NKG2 activation/inhibition balance is similar in
spite of a considerable heterogeneity in underlying ma-
lignancies, conditioning regimens, engraftment kinetics,
infection/clinical course, and allo/auto transplantationsettings. This suggests that NKG2 modulation is a stand-
ard response to HSCT procedures. Although this study
was not designed to address possible influences of
NKG2 up-regulation on survival, the only two outliers
with high R(act/inh) ratios coincided with the longest
and shortest survivors within the allotransplantation and
autotransplantation groups (Additional file 1: Figure S1).
Fig. 3 Engraftment and the expression of NKG2A, NKG2C and NKG2D. Percent engraftment (assessed by VNTR) and percent of CD8+ and CD56+
WBCs positive for NKG2A, NKG2C and NKG2D (double scale in ordinates) were plotted against time elapsed from HSCT
Picardi et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:98 Page 7 of 11Pt 155 displayed an immature (CD56-high) post-transplant
immunophenotype similar to the other allotransplanted
patients. Pt 187 displayed a marginal increase in CD56 mfi
similar to autotransplanted pts 189 and 190 (Additional
file 1: Table S3). Altogether, high R(act/inh) ratios appear
to be the only distinctive feature of pts 155 and 187, in the
context of the limited testing performed herein.Expression of NKG2 ligands in hematologic malignancies
from patients undergoing autotransplantation
Diagnostic biopsies (available in three cases) were assessed
by immunohistochemistry for the expression of HLA-E
(the ligand of inhibitory NKG2A and activating NKG2C
receptors), and for MICA, ULBP-1, ULBP-2 and ULBP-3
(the ligands of the activating NKG2D receptor), as
described in Methods. Representative results are shown in
Fig. 5, and a synopsis is provided in Table 3. From 2 to 3
of the 5 tested NKG2 ligands were constitutively expressed,
although with different intensities, by tumor cells (and oc-
casionally by background lymphocytes) prior to HSCT
(T0). In addition, serial bone marrow biopsies were available
at four time points for a multiple myeloma: two were
obtained before transplantation (T0), and two after relapse.
One representative lesion of each kind is shown in Fig. 5e
and f, and the results are summarized in Table 3. As com-
pared to T0 biopsies, both biopsies taken at relapse dis-
played increased HLA-E stain, and de novo appearance of
MICA and ULBP-1 expression. Altogether, 4 out of 5 tested
NKG2 ligands became expressed in this multiple myeloma
after HSCT. These results show that in some patients
undergoing autologous HSCT there is a paired up-
regulation/high expression of the NKG2A/C/D receptorson circulating immune effectors, and of their cognate
tumor immune ligands on hematopoietic malignancies.
This suggests potential receptor:ligand interplay in vivo.Discussion
The ability of mature NK cells to be re-educated and
adapt to the environment [25–27] provides a solid ration-
ale to their use in HSCT. Interaction of inhibitory NKG2A
with self-HLA ligands is a prominent NK cell licencing
checkpoint [28]. Accordingly, NKG2A overexpression
accompanied by KIR down-regulation, and occasionally
CD56 up-regulation, has been concordantly detected in all
the available HSCT studies [12–18].Simultaneous up-regulation of NKG2A, NKG2C and NKG2D
In the present report, we show that not only inhibitory
NKG2A, but also receptors mediating activation
(NKG2C and NKG2D) are simultaneously up-regulated
in HSCT. It has been shown that activating NKG2 re-
ceptors, although expressed at low levels, may overcome
the inhibitory NKG2A block in NK cells, contributing to
antimicrobial defense [29]. Thus, apart from its potential
ability to trigger NK cell maturation and foster GvT,
NKG2C/D up-regulation during engraftment may be
beneficial to control infection in immunosuppressed
patients [30]. As noted by several authors, NK cell
receptor plasticity lasts several months, but NKG2A
levels return to baseline donor levels thereafter [13, 14].
Accordingly, we have shown herein that engraftment
occurs between days 30 and 90 in essentially all the
allotransplanted patients, and is accompanied or im-
mediately followed by receptor up-regulation. Based
CD8 CD56
T0 (pre-transplant) T90 post-transplantT30 post-transplant

















































































































Fig. 4 Quantitative evaluation of NKG2A, NKG2C and NKG2D levels following autologous HSCT. Flow cytometry data obtained from 5 patients
were graphically elaborated exactly as in Fig. 2. Panels in which NKG2 up-regulation is clearly detectable are in grey
Picardi et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:98 Page 8 of 11on these data, attempts to turn the balance of dual recog-
nition toward triggering should be made within this time
window.
NKG2 up-regulation on both T and NK cells
It is not surprising that NKG2 up-regulation is general-
ized, e.g. it involves both CD56+ populations (largely
including NK cells), as shown by several groups, and
CD8+ T cells, as shown herein. NK cells integrate oppos-
ing influences by default [31], but this functional mode
may also be adopted by anti-tumor T lymphocytes [32].
In addition, the classical separation between innate and
adaptive immunity has recently been blurred [33]. Dif-
ferences remain, in that NK cell education/licensing is a
dynamic process requiring continuous sampling of MHC
class I ligands, whereas positive selection of T cells is aone-time event [25–27, 33]. However, the present obser-
vation that NKG2 up-regulation also occurs on engraft-
ing T cells suggests that these may undergo permanent,
NK cell-like education/re-tuning. Evidence has indeed
been provided that CD94:NKG2C expressed on certain
T cell subsets may drive T cell expansion and triggering
of effector functions [20]. This is particularly relevant to
the autotransplantation setting, in which up-regulation
was more marked on T than NK cells. We have recently
reviewed the available evidence indicating that it takes
both T and NK cells to mount effective antitumor immune
responses [34].
NKG2 up-regulation, engraftment and stress
NKG2 up-regulation either coincides with (beginning on












Fig. 5 Immunohistochemical staining with mAb MEM-E/02 to HLA-E. HLA-E is strongly expressed in the bone lytic localizations of a Diffuse Large
B Cell Lymphoma (panel a; pt 188; score = 2), but not in a case of Hodgkin’s Lymphoma (b; pt 190; score = 0), although isolated cells with histiocytic
appearance show weak cytoplasmic stain. The same case of Hodgkin Lymphoma moderately expresses ULBP-1 and ULBP-2 in Hodgkin’s
cells and Reed-Sternberg cells (c and d; score = 1). Background lymphocytes moderately express ULBP-1 (c). A bone marrow biopsy of a Multiple Myeloma
is strongly reactive for HLA-E (e; pt 191; score = 2), and this reactivity is enhanced and becomes highly diffuse (f; score = 3) at relapse, 880 days post-
transplant. All panels FFPE tissues; 400x magnification
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ing place on cells of donor origin, as expected. Although
access to primary data may be required to draw rigorous
conclusions, comparison among the only available report
on haploidentical transplantation [14], the numerous stud-
ies on HLA-matched allotransplantation [12, 13, 15–18]
including the present one, and the present results onTable 3 Summary of Immunohistochemical testing of neoplastic
lesions from autotransplanted patients
Time HLA-E MICA ULBP-1 ULBP-2 ULBP-3
pt 188 (DLBCL) T0 2 0 1 2 0
pt 190 (HL) T0 0 0 2 2 0
pt 191 (MM) T0 2 0 0 2 0
Relapse 3 1 1 2 0
DLBCL Diffuse Large B cell Lymphoma, HL Hodgkin Lymphoma, MM
Multiple Myelomaautotransplanted patients (not tested before) suggests that
NKG2A up-regulation is greatest, intermediate and min-
imal, respectively, in these three settings. Likewise, CD56
up-regulation, previously detected in allotransplanted
patients [14, 16–18], was shown herein to also occur in
autotransplanted patients, but to a lesser extent. Thus,
there is a gradient: the greater the genetic/phenotypic
mismatch, the greater the extent of phenotypic up-
regulation. Altogether, the timing and gradient of
NKG2 up-regulation suggest the co-existence of im-
mune re-education and a general stress response to
pre-transplant chemotherapy and post-transplant re-
population. Possibly, chemotherapy without transplant-
ation may give rise to similar effects, as long as immune
effectors are given the chance to recover and become
re-educated. It will be of interest to assess NKG2 up-
regulation in cancer patients with an un-manipulated
hematopoietic compartment.
Picardi et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:98 Page 10 of 11Implications of NKG2 up-regulation
Although we are not aware of large randomized studies,
high persistent expression of inhibitory NKG2A on donor
NK cells has been associated with a poor transplantation
outcome in HLA-matched [12, 13] and haploidentical [14]
HSCT. In the present study, we found that the extent of
up-regulation of the individual NKG2 receptors and the
ratio of activation vs inhibition were similar in most
patients. Therefore, much larger numbers of patients are
necessary to determine whether taking into account more
receptors might provide additional prognostic information.
However, 2/12 tested patients displayed a clear preva-
lence of activating receptor expression. It is apparently
counterintuitive that these two outliers are also the lon-
gest and shortest survivors in the allotransplant (pt. 155)
and autotransplant (pt. 187) groups, respectively, and
that the former displays a CD56-high post-transplant
phenotype suggesting persistence of immature NK cells.
Possibly, a prevalence of activating NKG2 receptor expres-
sion may have a biological role in the allotransplant set-
ting, in which it occurs on both T and NK cells, but not in
the autotransplant setting, in which NKG2 up-regulation
is much weaker and T cell-selective. Alternatively, or in
addition, receptor engagement with certain tumor ligands
may primarily determine the prognosis, since NKG2
ligands were detected in essentially all the tested malig-
nancies, and in one patient they were found to be en-
hanced on post-transplant relapse. Systematic testing of
NKG2 receptors and their tumor ligands is necessary to
determine the effect of HSCT on the tumor-host interplay
in hematologic malignancies.
Whatever the interpretation, further studies are needed
focusing on subsets of HSCT patients with selected
hematological diseases. It will be of interest to assess the
functional and clinical outcomes of NKG2:ligand interac-
tions after up-regulation.
Conclusions
In this report, we have shown that activating NKG2C
and NKG2D receptors are up-regulated in transplanted
immune cells of donor origin as a result of HSCT proce-
dures. Of interest, previous studies have concordantly
shown that the ex vivo expansion of NK cells turns the
NK receptor balance toward activation, although the
entity of NKG2C and NKG2D up-regulation differs in
different reports [35, 36]. Possibly, this depends at least
in part on the source (PBMCs vs cord blood CD34+
stem cells) and protocols (feeder layers of irradiated
hematopoietic cells vs cytokines alone) for NK cell ex-
pansion. Thus, strategies of in vitro expansion and
in vivo triggering (e.g. by HSCT, as shown herein) of NK
cells show both overlapping and complementation, and
should be carefully thought out and combined for opti-
mal therapeutic efficacy.Additional file
Additional file 1: Supplemental Methods and Results. A supplementary
Table (Table S1) summarizing the pertinent literature. A supplemental
figure (Fig. S1) displaying correlations between NKG2 up-regulation and
survival. References. (PDF 324 kb)
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